Browsing Tag
Recce Pharmaceuticals
6 posts
Recce Pharmaceuticals stock rises as Phase 3 trial begins in Indonesia: Can RCE prove its anti-infective breakthrough?
Recce Pharmaceuticals (ASX:RCE) stock gained as it began a Phase 3 trial in Indonesia for diabetic foot infections. Explore what this means for investors and AMR.
Recce Pharmaceuticals advances R327 Gel towards Phase 3 after promising Phase II trial
Recce Pharmaceuticals Limited has announced significant success in its Phase II trial of RECCE 327 topical gel (R327G),…
Recce Pharmaceuticals secures approval for Phase 3 trial of R327G in Indonesia
Recce Pharmaceuticals Limited (ASX: RCE) has achieved a significant milestone in its quest to tackle diabetic foot infections…
Recce Pharmaceuticals to begin Phase 3 trials in Indonesia for diabetic foot infection treatment
Recce Pharmaceuticals Limited has received ethics approval from Indonesia’s Human Research Ethics Committee to initiate Phase 3 clinical…
Recce Pharmaceuticals secures phase II trial safety approval for breakthrough R327G treatment
Recce Pharmaceuticals Limited recently announced significant progress in its phase II clinical trial for RECCE 327 Topical Gel…
Recce Pharmaceuticals completes cohort dosing in R327 Phase I/II trial
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) continues its trajectory in pioneering a new class of Synthetic Antiinfectives, spotlighting its…